Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

Shanghai Operation Robot Secures RMB 100 Million Series C Funding for AI-Driven Surgical Robot Development

Fineline Cube Apr 22, 2025

Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100...

Company Deals

Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management

Fineline Cube Apr 22, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...

Company Drug

Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction

Fineline Cube Apr 22, 2025

China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...

Company Medical Device

Broncus Medical Secures NMPA Approval for BroncAblate in Lung Cancer Treatment

Fineline Cube Apr 22, 2025

Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced...

Company Drug

Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871

Fineline Cube Apr 22, 2025

Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...

Company Deals

Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China

Fineline Cube Apr 22, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...

Company Drug

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial

Fineline Cube Apr 22, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...

Company Drug

Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis

Fineline Cube Apr 21, 2025

China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...

Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

Fineline Cube Apr 21, 2025

Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...

Company Medical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

Fineline Cube Apr 21, 2025

Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...

Company Drug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

Fineline Cube Apr 21, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...

Company Drug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

Fineline Cube Apr 21, 2025

France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...

Company Drug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

Fineline Cube Apr 21, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Fineline Cube Apr 21, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Drug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

Fineline Cube Apr 21, 2025

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...

Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

Fineline Cube Apr 21, 2025

hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...

Company Deals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development

Fineline Cube Apr 21, 2025

China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...

Company Drug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Fineline Cube Apr 21, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...

Company Drug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 21, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...

Company Medical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Fineline Cube Apr 21, 2025

US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...

Posts pagination

1 … 226 227 228 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.